Morgan Stanley lowered the firm's price target on WW to $21 from $34.50 and keeps an Equal Weight rating on the shares. A mix shift from behavioral to clinic is happening far faster than the firm anticipated, but this comes with upside as well as "negative trade-offs," the analyst tells investors.
